CC BY-NC-ND 4.0 · Indian Journal of Medical and Paediatric Oncology 2021; 42(01): 100-107
DOI: 10.1055/s-0041-1729725
How I treat

How I Treat Metastatic Hormone-Sensitive Prostate Cancer?

Deepak Dabkara
1  Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
,
Debapriya Mondal
1  Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
,
Joydeep Ghosh
1  Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
,
Bivas Biswas
1  Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
,
Sandip Ganguly
1  Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
› Author Affiliations

Abstract

Androgen deprivation therapy (ADT) combined with docetaxel or antiandrogens (abiraterone, enzalutamide, or apalutamide) improved the outcomes in men with metastatic hormone-sensitive prostate cancer (mHSPC). When multiple options are available, the dilemma remains how to choose among these options. Similarly, issues of bone health, long-term side effects of therapies, and hereditary risk need to be discussed for comprehensive care. In the present article, we reviewed the relevant evidence for the treatment of mHSPC. ADT alone is not the current standard of care for most patients. In these times of plenty and price crisis, it is imperative to find the best option for treating these patients.



Publication History

Publication Date:
28 May 2021 (online)

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India